Predictive and prognostic factors of preeclampsia: Interest of PlGF and sFLT-1;Facteurs prédictifs et pronostiques de la prééclampsie : intérêt du dosage du PlGF et du sFLT-1

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 45, Issue 9, 2016, Pages 999-1008

  Vieillefosse, S ^a,b   Guibourdenche, J ^b,c,d,e   Atallah, A ^d,f   Haddad, B ^a,b   Fournier, T ^b,d,f   Tsatsaris, V ^b,c,d,e,f   Lecarpentier, E ^b,c,d,e,f  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Fondation PremUP   (France)

^c Institut Cochin   (France)

^d INSERM   (France)

^e DHU Risques et Grossesse   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Angiogenic factors; Biomarkers; Placental growth factor; PlGF; Prediction; Preeclampsia; Prognosis; SFlt 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN;

DISEASE SEVERITY; FEMALE; HUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY; PROGNOSIS; REVIEW; ADULT; BLOOD;

ADULT; BIOMARKERS; FEMALE; HUMANS; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84975470544     PISSN: 03682315     EISSN: 17730430     Source Type: Journal    
DOI: 10.1016/j.jgyn.2016.02.006     Document Type: Review

References (29)

1. [1] Mol, B.W.J., Roberts, C.T., Thangaratinam, S., Magee, L.A., de Groot, C.J.M., Hofmeyr, G.J., Pre-eclampsia. Lancet Lond Engl 387 (2015), 999–1011, 10.1016/S0140-6736(15)00070-7 [Epub 2015 Sep 2].
2. [2] Bujold, E., Roberge, S., Lacasse, Y., Bureau, M., Audibert, F., Marcoux, S., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116 (2010), 402–414, 10.1097/AOG.0b013e3181e9322a.
3. [3] Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Zeisler, H., Calda, P., et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63 (2014), 346–352, 10.1161/HYPERTENSIONAHA.113.01787.
4. [4] Maynard, S.E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003), 649–658, 10.1172/JCI17189.
5. [5] Levine, R.J., Maynard, S.E., Qian, C., Lim, K.-H., England, L.J., Yu, K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004), 672–683, 10.1056/NEJMoa031884.
6. [6] Conde-Agudelo, A., Romero, R., Lindheimer, M., Tests to predict preeclampsia. Lindhei-mer, M., Roberts, J., Cunningham, G.C., (eds.) Hypertensive disorders in pregnancy, 2009, Elsevier, 189–212 [Chapter 11.ISBN: 978-0-12-374213-1].
7. [7] Poon, L.C.Y., Kametas, N.A., Maiz, N., Akolekar, R., Nicolaides, K.H., First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53 (2009), 812–818, 10.1161/HYPERTENSIONAHA.108.127977.
8. [8] Akolekar, R., Syngelaki, A., Poon, L., Wright, D., Nicolaides, K.H., Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33 (2013), 8–15, 10.1159/000341264.
9. [9] Oliveira, N., Magder, L.S., Blitzer, M.G., Baschat, A.A., First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol 44 (2014), 279–285, 10.1002/uog.13435.
10. [10] Schiettecatte, J., Russcher, H., Anckaert, E., Mees, M., Leeser, B., Tirelli, A.S., et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem 43 (2010), 768–770, 10.1016/j.clinbiochem.2010.02.010.
11. [11] Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M.G., et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 202 (2010), 161.e1–161.e11, 10.1016/j.ajog.2009.09.016.
12. [12] Wothe, D., Gaziano, E., Sunderji, S., Romero, R., Kusanovic, J.P., Rogers, L., et al. Measurement of sVEGF R1 and PlGF in serum: comparing prototype assays from Beckman Coulter, Inc. to R&D Systems microplate assays. Hypertens Pregnancy 30 (2011), 18–27, 10.3109/10641950903322881.
13. [13] Sunderji, S., Gaziano, E., Wothe, D., Rogers, L.C., Sibai, B., Karumanchi, S.A., et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 202 (2010), 40.e1–40.e7, 10.1016/j.ajog.2009.07.025.
14. [14] Lee, M.S., Cantonwine, D., Little, S.E., McElrath, T.F., Parry, S.I., Lim, K.-H., et al. Angiogenic markers in pregnancies conceived through in vitro fertilization. Am J Obstet Gynecol 212-213 (2015), e1–e8, 10.1016/j.ajog.2015.03.032 [Epub 2015 Mar 19].
15. [15] Andersen, L.B., Frederiksen-Møller, B., Work Havelund, K., Dechend, R., Jørgensen, J.S., Jensen, B.L., et al. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens JASH 9 (2015), 86–96, 10.1016/j.jash.2014.11.008.
16. [16] Kenny, L.C., Black, M.A., Poston, L., Taylor, R., Myers, J.E., Baker, P.N., et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension 64 (2014), 644–652, 10.1161/HYPERTENSIONAHA.114.03578.
17. [17] Audibert, F., Boucoiran, I., An, N., Aleksandrov, N., Delvin, E., Bujold, E., et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol 203 (2010), 383.e1–383.e8, 10.1016/j.ajog.2010.06.014.
18. [18] Myatt, L., Clifton, R.G., Roberts, J.M., Spong, C.Y., Hauth, J.C., Varner, M.W., et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 119 (2012), 1234–1242, 10.1097/AOG.0b013e3182571669.
19. [19] Myers, J.E., Kenny, L.C., McCowan, L.M.E., Chan, E.H.Y., Dekker, G.A., Poston, L., et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG Int J Obstet Gynaecol 120 (2013), 1215–1223, 10.1111/1471-0528.12195.
20. [20] Crovetto, F., Figueras, F., Triunfo, S., Crispi, F., Rodriguez-Sureda, V., Dominguez, C., et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn, 2014, 10.1002/pd.4519.
21. [21] Thadhani, R., Mutter, W.P., Wolf, M., Levine, R.J., Taylor, R.N., Sukhatme, V.P., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89 (2004), 770–775, 10.1210/jc.2003-031244.
22. [22] Poon, L.C., Nicolaides, K.H., Early prediction of preeclampsia. Obstet Gynecol Int, 2014, 2014, 297397, 10.1155/2014/297397.
23. [23] Sibiude, J., Guibourdenche, J., Dionne, M.-D., Le Ray, C., Anselem, O., Serreau, R., et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PloS One, 7, 2012, e50208, 10.1371/journal.pone.0050208.
24. [25] Chappell, L.C., Duckworth, S., Seed, P.T., Griffin, M., Myers, J., Mackillop, L., et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 128 (2013), 2121–2131, 10.1161/CIRCULATIONAHA.113.003215.
25. [26] Rana, S., Powe, C.E., Salahuddin, S., Verlohren, S., Perschel, F.H., Levine, R.J., et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125 (2012), 911–919, 10.1161/CIRCULATIONAHA.111.054361.
26. [27] Stepan, H., Herraiz, I., Schlembach, D., Verlohren, S., Brennecke, S., Chantraine, F., et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol 45 (2015), 241–246, 10.1002/uog.14799.
27. [28] Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A.C., Sennström, M., et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. N Engl J Med 374 (2016), 13–22, 10.1056/NEJMoa1414838.
28. [29] Schaarschmidt, W., Rana, S., Stepan, H., The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med 41 (2013), 511–516, 10.1515/jpm-2012-0248.
29. [30] Baltajian, K., Bajracharya, S., Salahuddin, S., Berg, A.H., Geahchan, C., Wenger, J.B., et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol, 2016, 10.1016/j.ajog.2016.01.168 [pii: S0002-9378(16)00218-0].